Teva Pharmaceutical Industries Ltd.

Regulatory Filings • Mar 8, 2025

Check this box if no longer subject to Section 16. OMB Number: Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Estimated average burden hours per Instruction 1(b). Washington, D.C. 20549 response Check this box to indicate that a transaction was STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES made pursuant to a contract, instruction or written Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to Issuer 2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [ TEVA ] (Check all applicable) Sabag Mark _ Director 10% Owner (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) _ X __ Officer (give title below) ___ Other (specify below) C/O Teva Pharmaceutical Industries Ltd. 03/05/2025 See "Remarks"	FORM 4			OMB APPROVAL
	(Print or Type Responses)		3235-0287 0.5
124 Dvora HaNevi'a St.,
(Street) 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person Tel Aviv, L3 6944020 ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

(City) (State) (Zip)

1.Title of Security (Instr. 3)	2. Transaction Date (Month /Day/Year)	2A. Deemed Execution Date, if any (Month/Day /Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form:	7. Nature of Indirect Beneficial
			Code	V		Amount (A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Ordinary Shares (1)	03/05/2025		M		23,765	A	(2)	488,911	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month /Day/Year)	3A. Deemed Execution Date, if any (Month/Day /Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date (Month/Day/Year)	6. Date Exercisable and Expiration	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities	10. Ownership Form of Derivative	11. Nature of Indirect Beneficial Ownership
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Beneficially Owned Following Reported Transaction (s) (Instr. 4)	Security: Direct (D) or Indirect (I) (Instr. 4)	(Instr. 4)
Restricted Share Units	(2)	03/05/2025		M			23,765	(3)	(3)	Ordinary Shares (1)	23,765	\$ 0	0	D
Restricted Share Units	(2)	03/05/2025		A		62,893		(4)	(4)	Ordinary Shares (1)	62,893	\$ 0	62,893	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vested on March 5, 2025.

4. Restricted share units were granted on March 5, 2025, with 15,723 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.

Remarks:

Executive Vice President, International Markets Commercial

/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag 03/07/2025

Signature of Reporting Person ** Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.